Biopsies of primary and metastatic endometrial cancer samples detected TRPV2 and TRPC1 mRNA expression levels, observing a higher expression in metastatic samples and a correlating mesenchymal phenotype, which is a malignant hallmark of EC; in particular, TRPV2 expression predicted disease recurrence in primary tumor biopsies, indicating that TRPV2 may be a biomarker for EC progression [58]. This evidence concerns the gene TRPV2 and neoplasm.